Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

RxSight (RXST) Shares Outstanding (2020 - 2026)

RxSight filings provide 6 years of Shares Outstanding readings, the most recent being $41.2 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 2.01% to $41.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $41.2 million, a 2.01% increase, with the full-year FY2025 number at $41.2 million, up 2.01% from a year prior.
  • Shares Outstanding hit $41.2 million in Q4 2025 for RxSight, roughly flat from $41.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $41.2 million in Q4 2025 to a low of $4.1 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $35.5 million (2023), compared with a mean of $31.8 million.
  • Biggest five-year swings in Shares Outstanding: surged 2736674500.0% in 2021 and later grew 1.45% in 2022.
  • RxSight's Shares Outstanding stood at $27.4 million in 2021, then increased by 3.29% to $28.3 million in 2022, then rose by 27.84% to $36.1 million in 2023, then rose by 11.87% to $40.4 million in 2024, then increased by 2.01% to $41.2 million in 2025.
  • The last three reported values for Shares Outstanding were $41.2 million (Q4 2025), $41.1 million (Q3 2025), and $40.9 million (Q2 2025) per Business Quant data.